Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Nanotechnology solutions for mucosal immunization.

Chadwick S, Kriegel C, Amiji M.

Adv Drug Deliv Rev. 2010 Mar 18;62(4-5):394-407. doi: 10.1016/j.addr.2009.11.012. Epub 2009 Nov 18. Review.

PMID:
19931581
2.

Delivery strategies to enhance mucosal vaccination.

Chadwick S, Kriegel C, Amiji M.

Expert Opin Biol Ther. 2009 Apr;9(4):427-40. doi: 10.1517/14712590902849224 . Review.

PMID:
19344280
3.

Mucosal immunisation: adjuvants and delivery systems.

Moyle PM, McGeary RP, Blanchfield JT, Toth I.

Curr Drug Deliv. 2004 Oct;1(4):385-96. Review.

PMID:
16305400
4.

Nanocarriers for systemic and mucosal vaccine delivery.

Shahiwala A, Vyas TK, Amiji MM.

Recent Pat Drug Deliv Formul. 2007;1(1):1-9. Review.

PMID:
19075870
5.

Mucosal delivery of vaccine antigens and its advantages in pediatrics.

De Magistris MT.

Adv Drug Deliv Rev. 2006 Apr 20;58(1):52-67. Epub 2006 Mar 3. Review.

PMID:
16516335
6.

Delivery systems: a vaccine strategy for overcoming mucosal tolerance?

Mann JF, Acevedo R, Campo JD, PĂ©rez O, Ferro VA.

Expert Rev Vaccines. 2009 Jan;8(1):103-12. doi: 10.1586/14760584.8.1.103. Review.

PMID:
19093777
7.

Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.

Vajdy M, Srivastava I, Polo J, Donnelly J, O'Hagan D, Singh M.

Immunol Cell Biol. 2004 Dec;82(6):617-27. Review.

8.

Stimulation of local antibody production: parenteral or mucosal vaccination?

Bouvet JP, Decroix N, Pamonsinlapatham P.

Trends Immunol. 2002 Apr;23(4):209-13. Review.

PMID:
11923116
9.

Nanotechnology in vaccine delivery.

Peek LJ, Middaugh CR, Berkland C.

Adv Drug Deliv Rev. 2008 May 22;60(8):915-28. doi: 10.1016/j.addr.2007.05.017. Epub 2008 Feb 7. Review.

PMID:
18325628
10.

Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities.

Sharma R, Agrawal U, Mody N, Vyas SP.

Biotechnol Adv. 2015 Jan-Feb;33(1):64-79. doi: 10.1016/j.biotechadv.2014.12.004. Epub 2014 Dec 12. Review.

PMID:
25499178
11.

Recent advances in mucosal vaccine development.

Chen H.

J Control Release. 2000 Jul 3;67(2-3):117-28. Review.

PMID:
10825547
12.

Ensuring vaccine safety in immunization programmes--a WHO perspective.

Jodar L, Duclos P, Milstien JB, Griffiths E, Aguado MT, Clements CJ.

Vaccine. 2001 Feb 8;19(13-14):1594-605.

PMID:
11166881
13.

Poly(anhydride) nanoparticles as adjuvants for mucosal vaccination.

Irache JM, Salman HH, Gomez S, Espuelas S, Gamazo C.

Front Biosci (Schol Ed). 2010 Jun 1;2:876-90. Review.

PMID:
20515831
14.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
15.
16.

Mucosal adjuvants.

Harandi AM, Medaglini D.

Curr HIV Res. 2010 Jun;8(4):330-5. Review.

PMID:
20353395
17.

Mucosal immunization: a realistic alternative.

Otczyk DC, Cripps AW.

Hum Vaccin. 2010 Dec;6(12):978-1006. Epub 2010 Dec 1. Review.

PMID:
21150284
18.

Implication of nanoparticles/microparticles in mucosal vaccine delivery.

Vyas SP, Gupta PN.

Expert Rev Vaccines. 2007 Jun;6(3):401-18. Review.

PMID:
17542755
19.

Mechanisms of vaccine adjuvanticity at mucosal surfaces.

Foss DL, Murtaugh MP.

Anim Health Res Rev. 2000 Jun;1(1):3-24. Review.

PMID:
11706842
20.

Novel vaccine development strategies for inducing mucosal immunity.

Fujkuyama Y, Tokuhara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y, Kiyono H, Fujihashi K.

Expert Rev Vaccines. 2012 Mar;11(3):367-79. doi: 10.1586/erv.11.196. Review.

Items per page

Supplemental Content

Write to the Help Desk